Answers are grounded in this paper and cite their sources.
This case report highlights the potential role of flourodeoxyglucoce/positron emission tomography (FDG/PET) for diagnosis of occult high-risk prostate cancer during evaluation and follow-up for other malignancies.1 It also highlights the potential shortcomings of DIGITAL rectal exam (DRE) and PSA as the only means of prostate cancer diagnosis in select patients. In the index patient, the FDG/PET scan was abnormal with uptake in the prostate despite a low PSA and normal DRE. Despite the nonspecificity of FDG/PET for prostate cancer, this abnormal uptake should prompt a prostate MRI. It is hard to speculate if a prostate MRI would have been abnormal at that stage which would have been a year earlier. However, chances are that given the patient's extremely high-risk disease found the following year, the biopsy would have detected an already present disease a year earlier. Despite this speculative consideration, there is no question that once a diagnosis of high-risk prostate cancer was established with a rise in the PSA and a higher uptake in the FDG/PET scan, a PET/prostate specific membrane antigen (PSMA) scan would have been an ideal imaging modality for evaluation of possible prostate cancer metastases. A PET/PSMA scan has a higher sensitivity and specificity and positive predictive value for prostate cancer and should be the imaging modality of choice before definitive therapy for prostate cancer, especially for high-risk disease such as the case presented here. The patient's PSA in this report is currently undetectable, but this is very short-term follow-up. There was not a large number of lymph nodes removed, and despite negative margins, the patient does have a high risk for recurrence. This report highlights the chance for high-risk occult prostate cancer in patients who undergo FDG/PET scanning for other malignancies. A high index of suspicion is necessary, prompting a prostate MRI evaluation. Once a suspicious lesion is detected on MRI, a follow-up MRI fusion biopsy should be obtained with a PET/PSMA scan for evaluation of occult prostate cancer metastases and as a baseline study to follow after definitive local therapy.
No takes yet. Share an insight, caveat, or question.
Reza Ghavamian (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: